Volume 14, Number 8—August 2008
Ciprofloxacin Resistance in Neisseria meningitidis, France
Highlight and copy the desired format.
|EID||Skoczynska A, Alonso J, Taha M. Ciprofloxacin Resistance in Neisseria meningitidis, France. Emerg Infect Dis. 2008;14(8):1322-1323. https://dx.doi.org/10.3201/eid1408.080040|
|AMA||Skoczynska A, Alonso J, Taha M. Ciprofloxacin Resistance in Neisseria meningitidis, France. Emerging Infectious Diseases. 2008;14(8):1322-1323. doi:10.3201/eid1408.080040.|
|APA||Skoczynska, A., Alonso, J., & Taha, M. (2008). Ciprofloxacin Resistance in Neisseria meningitidis, France. Emerging Infectious Diseases, 14(8), 1322-1323. https://dx.doi.org/10.3201/eid1408.080040.|
To the Editor: Infections with Neisseria meningitidis may occur as outbreaks or epidemics. Consequently, chemoprophylaxis for contacts is generally recommended. Ciprofloxacin is frequently used in adults in a convenient 1-dose regimen (1). Resistance to this antimicrobial drug in N. meningitidis is rare (MIC>0.06 mg/L) and has been reported only in sporadic cases in Greece, France, Australia, Spain, Argentina and Hong Kong Special Administrative Region, People’s Republic of China (2–5). However, recent reports have described ciprofloxacin-resistant (Cip-R) serogroup A meningococci from 2 outbreaks in Delhi, India (6), and a cluster of 3 serogroup B meningococci in the United States (7). This information is of concern because of the high epidemic potential of serogroup A isolates, lack of vaccine against serogroup B meningococci, and possible horizontal Cip-R gene transfer to other meningococcal isolates.
Experimental work was conducted in the Neisseria Unit of the Institut Pasteur in Paris. We screened all clinical N. meningitidis isolates received at the French National Reference Center for Meningococci in Paris since 1999 for ciprofloxacin resistance. Of these isolates, 4,900 were from France and 246 were from African countries (Burkina Faso, Cameroon, Central African Republic, Côte d’Ivoire, Madagascar, Niger, Rwanda, Senegal, and Tunisia). Only 3 isolates tested were resistant to ciprofloxacin (MICs = 0.19 mg/L), and all were isolated from cases of invasive disease in France.
Two serogroup A, serotype 4, serosubtype P1.9, Cip-R isolates belonged to different sequence types (STs), ST-7 (Cip-R1) and ST-4789 (Cip-R2), although they belonged to the same clonal complex (ST-5/subgroup III). Cip-R1, which showed decreased susceptibility to penicillin, was isolated in 2004 from the blood of a 7-year-old girl. This isolate was most likely imported from Africa. Cip-R2 was isolated from the cerebrospinal fluid of a 77-year-old man who had arrived in France from India in 2006. The ST of this isolate (ST-4789) is the same as the ST of isolates from an outbreak in Bangladesh and similar to isolates from an outbreak in India (6; http://neisseria.org/nm/typing/mlstdb). Cip-R3 (serogroup W-135, nontypeable, subtype P1.5), which was isolated from blood and cerebrospinal fluid of an 82-year-old woman in 2006, belonged to a new ST (ST-6361). Current ciprofloxacin resistance has not been documented among invasive W-135 meningococcal isolates since 2 W-135 resistant meningococci were isolated from sputum samples of elderly patients in Spain (3).
To investigate the mechanism of resistance in the isolates, fragments of gyrA (847 bp) and parC (822 bp) genes were amplified by using primers gyrA-1F (5′-gttttcccagtcacgacgttgtaATGACCGACGCAACCATCCGCCAC-3′) and gyrA-1R (5′-ttgtgagcggataacaatttcCCAGCTTGGCTTTGTTGACCTGATAG-3′), and parC-1F (5′-gttttcccagtcacgacgttgtaATGAATACGCAAGCGCACGCCCCA-3′) and parC-1R (5′-ttgtgagcggataacaatttcGGAATTGGCGTTCGGCGGCAGCTC-3′), respectively (sequences in lower case letters are adaptors for universal forward and reverse sequences were added for sequencing after amplification). Primers used for amplification of the parE gene were as described (8).
Sequencing of fragments of gyrA, parC, and parE genes showed a mutation in the gyrA gene in the 3 Cip-R isolates resulting in a Thr91 → Ile substitution. Cip-R1 also showed additional alterations of Asn103 → Asp, Ile111 → Val, and Val120 → Ile, which were described for meningococcal isolates (3). Sequences of parC and parE genes were the same as in a ciprofloxacin-susceptible isolate tested. The association of the Cip-R phenotype with mutations in gyrA was confirmed by transformation into the susceptible isolate by using appropriate PCR products (9). In addition to the common Thr91 → Ile substitution, the 3 Cip-R isolates were distinguishable by additional gyrA alterations or phenotypic and genotypic characteristics. This finding suggests independent events and argues against clonal expansion of Cip-R meningococci.
Serogroup A meningococcal isolates in France are rare and mostly imported. Lack of detection of ciprofloxacin resistance among African isolates tested in this study may be caused by the relatively low number of these isolates (n = 246). Therefore, surveillance of antimicrobial drug susceptibility of meningococcal isolates should be enhanced by using molecular approaches that can also be used as nonculture techniques. This molecular approach will be useful in countries with limited access to classic microbiologic culture–based methods. Reports of invasive cases caused by W-135 Cip-R meningococci should alert physicians who use quinolones to treat respiratory infections in elderly persons. This age group is affected most often by invasive meningococcal pneumonia and 54.5% of such cases are caused by W-135 meningococci (10).
A.S. was supported by a Marie Curie Intra-European Fellowship (no. 23188) within the Sixth European Community Framework Program.
- Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC).Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2005;54(RR-7):1–21.
- Shultz TR, Tapsall JW, White PA, Newton PJ. An invasive isolate of Neisseria meningitidis showing decreased susceptibility to quinolones.Antimicrob Agents Chemother. 2000;44:1116.
- Enriquez R, Abad R, Salcedo C, Perez S, Vazquez JA. Fluoroquinolone resistance in Neisseria meningitidis in Spain.J Antimicrob Chemother. 2008;61:286–90.
- Corso A, Faccone D, Miranda M, Rodriguez M, Regueira M, Carranza C, Emergence of Neisseria meningitidis with decreased susceptibility to ciprofloxacin in Argentina.J Antimicrob Chemother. 2005;55:596–7.
- Chu YW, Cheung TK, Tung V, Tiu F, Lo J, Lam R, A blood isolate of Neisseria meningitidis showing reduced susceptibility to quinolones in Hong Kong.Int J Antimicrob Agents. 2007;30:94–5.
- Singhal S, Purnapatre KP, Kalia V, Dube S, Nair D, Deb M, Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India.Emerg Infect Dis. 2007;13:1614–6.
- Centers for Disease Control and Prevention. Emergence of fluoroquinolone-resistant Neisseria meningitidis—Minnesota and North Dakota, 2007–2008.MMWR Morb Mortal Wkly Rep. 2008;57:173–5.
- Lindbäck E, Rahman M, Jalal S, Wretlind B. Mutations in gyrA, gyrB, parC, and parE in quinolone-resistant strains of Neisseria gonorrhoeae.APMIS. 2002;110:651–7.
- Antignac A, Kriz P, Tzanakaki G, Alonso JM, Taha MK. Polymorphism of Neisseria meningitidis penA gene associated with reduced susceptibility to penicillin.J Antimicrob Chemother. 2001;47:285–96.
- Vienne P, Ducos-Galand M, Guiyoule A, Pires R, Giorgini D, Taha MK, The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia.Clin Infect Dis. 2003;37:1639–42.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Anna Skoczynska, National Reference Centre for Bacterial Meningitis, National Medicines Institute, Chelmska 30/34, Warsaw, Poland;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 12, 2010
- Page last updated: July 12, 2010
- Page last reviewed: July 12, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)